Search Medical Condition
Please enter condition
Please choose location from dropdown

Sungnam, Korea, Republic of Clinical Trials

A listing of Sungnam, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (345) clinical trials

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers

Phase

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC but have progressed on or are intolerant to Next Generation Hormonal Agent ...

Phase

0.0 miles

Learn More »

Effect of Aging & Obesity With Exercise Intervention

This study is prospective study. The goal of this study is To examine the distribution and contractile properties (cross-sectional area, maximal force, specific force, maximal shortening velocity) of single muscle fiber sex/Myosin heavy chain (MHC) type-related differences, by extracting a single muscle fiber from the vastus lateralis in young men ...

Phase N/A

0.0 miles

Learn More »

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Phase

0.0 miles

Learn More »

Ten-Year Outcomes of PRE-COMBAT Trial

This study is an extended one of PRECOMBAT trial.

Phase N/A

0.0 miles

Learn More »

A Study of Apalutamide in Participants With High Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

High-risk prostate cancer accounts for approximately 15 percent (%) of newly diagnosed prostate cancers. A systemic therapy that eradicates micrometastatic disease is needed to improve survival in high-risk participants undergoing radical prostatectomy. It is hypothesized that androgen blockade prior to and after radical prostatectomy may improve outcomes for participants at ...

Phase

0.0 miles

Learn More »

AZD8186 and Paclitaxel in Advanced Gastric Cancer

AZD8186 is an orally-dosed, selective Phosphatidylinositol 3-kinase (PI3K) / inhibitor that binds to PI3K and PI3K, and inhibits kinase activity and downstream pathways in vitro and in vivo. AZD8186 has shown significant anti-tumor activity in PTEN-deficient preclinical models, including prostate, triple negative breast cancer, squamous lung and germinal center diffuse ...

Phase

0.0 miles

Learn More »

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer (TNBC)

Phase

0.0 miles

Learn More »

Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients

UCB is a high-quality source of mesenchymal stem cells, and studies are being actively developed for stroke patients. UCB therapy has neuroprotective effect through anti-inflammatory effect and anti-apoptosis. However, UCB alone has not been able to provide sufficient improvement and is being studied for combination therapies with growth factors that ...

Phase

0.0 miles

Learn More »

Biofreedom Prospective Multicenter Observational Registry

Percutaneous coronary intervention (PCI) and related interventional cardiology field are rapidly growing in current era. First generation drug eluting stent (DES) needed long-term dual antiplatelet therapy (DAPT) for preventing future stent thrombosis. But, second generation DES showed better clinical outcomes in terms of target lesion revascularization and stent thrombosis. Later, ...

Phase N/A

0.0 miles

Learn More »